

ICMJE DISCLOSURE FORM

Date: 7th Sep. 2022

Your Name: Sadahisa Ogasawara

Manuscript Title: How we use hepatic arterial infusion chemotherapy in the new era of systemic therapy?

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Bayer Yakuin Ltd.	
		Eisai Co., Ltd.	
		Eli Lilly Japan K.K.	
		Chugai Pharmaceutical Co., Ltd.	
		AstraZeneca K.K.	
		Gilead Sciences Inc.	
3	Royalties or licenses	None	

4	Consulting fees	Bayer Yakuhin Ltd.	
		Eisai Co., Ltd.	
		Eli Lilly Japan K.K.	
		Chugai Pharmaceutical Co., Ltd.	
		AstraZeneca K.K.	
		Merck & Co., Inc.	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Bayer Yakuhin Ltd.	
		Eisai Co., Ltd.	
		Eli Lilly Japan K.K.	
		Chugai Pharmaceutical Co., Ltd.	
		AstraZeneca K.K.	
		Takeda Pharmaceutical Co., Ltd.	
		AbbVie G.K.	
		Gilead Sciences Inc.	
Merck & Co., Inc.			
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Please summarize the above conflict of interest in the following box:

Sadahisa Ogasawara received honoraria from Bayer Yakuhin Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Takeda Pharmaceutical Co., Ltd., AbbVie G.K., Gilead Sciences Inc., and Merck & Co., Inc., consulting or advisory fees from Bayer Yakuhin Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., and Merck & Co., Inc., and research grants from Bayer Yakuhin Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., and Gilead Sciences Inc.

Please place an “X” next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7th Sep. 2022

Your Name: Naoya Kanogawa

Manuscript Title: How we use hepatic arterial infusion chemotherapy in the new era of systemic therapy?

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Japan Lifeline	
		COVIDIEN Japan	
		Kowa Company	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Please summarize the above conflict of interest in the following box:

Naoya Kanogawa received honoraria from Japan Lifeline, COVIDIEN Japan, and Kowa Company.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7th Sep. 2022

Your Name: Naoya Kato

Manuscript Title: How we use hepatic arterial infusion chemotherapy in the new era of systemic therapy?

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Ohtsuka Pharmaceutical Co., Ltd.	
		Bayer Yakuhin Ltd.	
		Chugai Pharmaceutical Co., Ltd.	
		Mitsubishi Tanabe Pharma Corporation	
		Sumitomo Dainippon Pharma Co., Ltd.	

		Shionogi & Co., Ltd.	
		Eisai Co., Ltd.	
		Tsumura & Co.	
		Nippon Kayaku Co., Ltd.	
		JIMRO Co., Ltd.	
		Kowa Company, Ltd.	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Gilead Sciences Inc.	
		AbbVie G.K.	
		Ohtsuka Pharmaceutical Co., Ltd.	
		Bayer Yakuhin Ltd.	
		Chugai Pharmaceutical Co., Ltd.	
		AstraZeneca K.K.	
		Sumitomo Dainippon Pharma Co., Ltd.	
		Takeda Pharmaceutical Co., Ltd.	
		Zeria Pharmaceutical Co., Ltd.	
		Olympus Corporation	
		Eisai Co., Ltd.	
		Aska Pharmaceutical Co., Ltd.	
		Tsumura & Co.	
		Mochida Pharmaceutical Co., Ltd.	
		Miyarisan Pharmaceutical Co., Ltd.	
		Covidien Japan Inc.	
		Eli Lilly Japan K.K.	
		Novelpharma Co., Ltd.	
		Kowa Company, Ltd.	
		Incyte Biosciences Japan GK	
		Yakult Honsha Co., Ltd.	
		Olympus Marketing, Inc.	
		Taisho Pharmaceutical Co., Ltd.	
		Janssen Pharmaceutical K.K.	

6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Please summarize the above conflict of interest in the following box:

Naoya Kato received honoraria from Gilead Sciences Inc., AbbVie G.K., Ohtsuka Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Olympus Corporation, Eisai Co., Ltd., Aska Pharmaceutical Co., Ltd., Tsumura & Co., Mochida Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Covidien Japan Inc., Eli Lilly Japan K.K., Novelpharma Co., Ltd., Kowa Company, Ltd., Incyte Biosciences Japan GK, Yakult Honsha Co., Ltd., Olympus Marketing, Inc., Taisho Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K., and research grants from Ohtsuka Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Ltd., Eisai Co., Ltd., Tsumura & Co., Nippon Kayaku Co., Ltd., JIMRO Co., Ltd., and Kowa Company, Ltd.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.